Ablynx NV (XBRU:ABLXS) Common Stock : €117.82 Mil (As of Dec. 2017)

View and export this data going back to . Start your Free Trial

What is Ablynx NV Common Stock?

Ablynx NV's quarterly common stock increased from Dec. 2016 (€106.06 Mil) to Jun. 2017 (€107.24 Mil) and increased from Jun. 2017 (€107.24 Mil) to Dec. 2017 (€117.82 Mil).

Ablynx NV's annual common stock increased from Dec. 2015 (€96.29 Mil) to Dec. 2016 (€106.06 Mil) and increased from Dec. 2016 (€106.06 Mil) to Dec. 2017 (€117.82 Mil).

Ablynx NV Common Stock Historical Data

The historical data trend for Ablynx NV's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ablynx NV Common Stock Chart

Ablynx NV Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Common Stock

Get a 7-Day Free Trial

84.00

91.98

96.29

106.06

117.82

Ablynx NV Semi-Annual Data
	Dec07	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17
Common Stock	Get a 7-Day Free Trial															96.29	105.88	106.06	107.24	117.82

Ablynx NV Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Ablynx NV (XBRU:ABLXS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ablynx NV (XBRU:ABLXS) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.ablynx.com

Ablynx NV is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It has 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. It has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The company generates revenue from research collaboration agreements and from government grants.

Ablynx NV (XBRU:ABLXS) Headlines

No Headlines